Glaukos Poised To Surpass Expectations And Raise Outlook In Q2 FY23, Fueled By iStent And iAccess Launches: Analyst
Portfolio Pulse from Vandana Singh
Needham expects Glaukos Corp (GKOS) to surpass expectations and raise its Q2 FY23 outlook, driven by rebounding iStent inject volumes and the accelerating iAccess and iPRIME launches. The analyst firm maintains a Buy rating and raises the price target to $89 from $67. Glaukos could see increasing iStent momentum before favorable ASC facility fee changes in 2024. The changes could potentially drive $10 million in revenue to GKOS in 2024.
July 19, 2023 | 6:26 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Sight Sciences Inc is mentioned in the context of the number of procedures it is estimated to perform in 2024. However, the news does not provide any specific outlook or rating for the company.
Sight Sciences Inc is mentioned in the news, but only in the context of the number of procedures it is estimated to perform in 2024. The news does not provide any specific outlook or rating for the company, so the impact on its stock price is uncertain.
CONFIDENCE 70
IMPORTANCE 20
RELEVANCE 20
POSITIVE IMPACT
Glaukos Corp is expected to surpass Q2 FY23 expectations and raise its outlook, driven by its iStent and iAccess products. This could potentially drive $10 million in revenue to GKOS in 2024.
The news is directly about Glaukos Corp and its products. The positive outlook and raised price target by Needham are likely to boost investor confidence, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100